• Cabaletta Bio outlined plans to submit a BLA for rese-cel in dermatomyositis in 2H27, including adult DM and juvenile DM data.
• Safety update across 63 preconditioned patients: 94% had no CRS or Grade 1 CRS; 97% had no ICANS, supporting outpatient use.
• In Phase 1/2 DM, 83% of adult patients would have met the registrational endpoint; the first JDM patient maintained response at 32 weeks.
• Systemic sclerosis positioned as the second pivotal indication; a roughly 25-patient single-arm registrational study is expected to start in 4Q26.
• PC-free rese-cel showed deep B-cell depletion in some lupus and pemphigus vulgaris patients; automated manufacturing with Cellares highlighted to cut COGS.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cabaletta Bio Inc. published the original content used to generate this news brief on June 03, 2026, and is solely responsible for the information contained therein.